Vertex Pharmaceuticals (VRTX): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Vertex Pharmaceuticals ( VRTX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 0.9%. By the end of trading, Vertex Pharmaceuticals fell $2.11 (-2.6%) to $79.80 on average volume. Throughout the day, 2,037,062 shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 1,727,900 shares. The stock ranged in price between $79.65-$83.24 after having opened the day at $82.37 as compared to the previous trading day's close of $81.91. Other companies within the Drugs industry that declined today were: Pain Therapeutics ( PTIE), down 6.9%, Cardium Therapeutics ( CXM), down 6.8%, Synthetic Biologics ( SYN), down 6.8% and Inovio Pharmaceuticals ( INO), down 6.4%.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. Vertex Pharmaceuticals has a market cap of $17.6 billion and is part of the health care sector. Shares are up 90.1% year to date as of the close of trading on Tuesday. Currently there are 11 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.

On the positive front, Questcor Pharmaceuticals ( QCOR), up 28.4%, Reliv' International ( RELV), up 22.0%, Galectin Therapeutics ( GALT), up 15.3% and GW Pharmaceuticals PLC ADR ( GWPH), up 14.6% , were all gainers within the drugs industry with Valeant Pharmaceuticals International ( VRX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

European and U.S. Stocks Called Higher as Earnings Season Hits Full-Speed

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC